WO2009020058A1 - 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー - Google Patents

脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー Download PDF

Info

Publication number
WO2009020058A1
WO2009020058A1 PCT/JP2008/063838 JP2008063838W WO2009020058A1 WO 2009020058 A1 WO2009020058 A1 WO 2009020058A1 JP 2008063838 W JP2008063838 W JP 2008063838W WO 2009020058 A1 WO2009020058 A1 WO 2009020058A1
Authority
WO
WIPO (PCT)
Prior art keywords
demyelinating
demyelinating lesion
lesion
drug delivery
delivery system
Prior art date
Application number
PCT/JP2008/063838
Other languages
English (en)
French (fr)
Inventor
Jin Nakahara
Sadakazu Aiso
Norihiro Suzuki
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Priority to US12/671,856 priority Critical patent/US8252540B2/en
Priority to JP2009526431A priority patent/JPWO2009020058A1/ja
Publication of WO2009020058A1 publication Critical patent/WO2009020058A1/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Abstract

　脱髄病変へのドラッグデリバリーシステムを提供する。また、脱髄病変の生化学的マーカーを提供する。 　コンタクチンを特異的に認識できる物質が、脱髄疾患の予防及び／又は治療薬の有効成分に結合していることを特徴とする、脱髄疾患の予防及び／又は治療薬デリバリーシステム。体液におけるコンタクチンの発現を測定することを含む、脱髄疾患の評価及び／又は鑑別方法。
PCT/JP2008/063838 2007-08-03 2008-08-01 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー WO2009020058A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/671,856 US8252540B2 (en) 2007-08-03 2008-08-01 Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion
JP2009526431A JPWO2009020058A1 (ja) 2007-08-03 2008-08-01 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007202776 2007-08-03
JP2007-202776 2007-08-03

Publications (1)

Publication Number Publication Date
WO2009020058A1 true WO2009020058A1 (ja) 2009-02-12

Family

ID=40341292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063838 WO2009020058A1 (ja) 2007-08-03 2008-08-01 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー

Country Status (3)

Country Link
US (1) US8252540B2 (ja)
JP (1) JPWO2009020058A1 (ja)
WO (1) WO2009020058A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015132628A (ja) * 2009-08-07 2015-07-23 アフィニマーク テクノロジーズ，インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112034176B (zh) * 2020-07-09 2022-08-30 中国工程物理研究院材料研究所 Cntn1作为长期低剂量电离辐射暴露诊断的分子标记物的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040995A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Method for estimating metabolic function of xenobiotic and induction thereof
JP2003504007A (ja) * 1999-05-19 2003-02-04 マイトコー 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
WO2003011337A1 (en) * 2001-07-30 2003-02-13 Keio University MEDICINAL COMPOSITIONS CONTAINING Fc RECEPTOR Ϝ-CHAIN ACTIVATOR
US20030054397A1 (en) * 2001-09-12 2003-03-20 David Leppert Methods and compositions for the detection and treatment of multiple sclerosis
WO2005007892A1 (en) * 2003-07-03 2005-01-27 Gentron, Llc Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040996A2 (en) 2000-11-08 2002-05-23 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
AU2002225219A1 (en) * 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
JP4594588B2 (ja) * 2001-04-10 2010-12-08 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ 抗体特異的プロファイルの治療的および診断的使用方法
WO2008085094A1 (en) 2007-01-10 2008-07-17 Volvo Lastvagnar Ab Hydraulic pump arrangement.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504007A (ja) * 1999-05-19 2003-02-04 マイトコー 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
WO2002040995A2 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Method for estimating metabolic function of xenobiotic and induction thereof
WO2003011337A1 (en) * 2001-07-30 2003-02-13 Keio University MEDICINAL COMPOSITIONS CONTAINING Fc RECEPTOR Ϝ-CHAIN ACTIVATOR
US20030054397A1 (en) * 2001-09-12 2003-03-20 David Leppert Methods and compositions for the detection and treatment of multiple sclerosis
WO2005007892A1 (en) * 2003-07-03 2005-01-27 Gentron, Llc Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015132628A (ja) * 2009-08-07 2015-07-23 アフィニマーク テクノロジーズ，インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法

Also Published As

Publication number Publication date
US8252540B2 (en) 2012-08-28
US20110250214A1 (en) 2011-10-13
JPWO2009020058A1 (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2010030728A3 (en) Devices and systems for delivery of therapeutic agents to body lumens
WO2010028090A3 (en) Agent delivery catheters
WO2007121143A3 (en) Microcatheter devices and methods for targeted substance delivery
WO2010141377A3 (en) Method and system for directing a localized biological response to an implant
IL187667A0 (en) System and method for navigating a surgical needle toward an organ of the body of a patient
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
EP1898795A4 (en) MEDICAL DOPPLER ULTRASOUND SYSTEM FOR LOCALIZING AND TRACKING BLOOD FLOW
WO2010057082A3 (en) Diagnostic capsules, delivery/retrieval systems, kits and methods
BRPI0812479A2 (pt) sistema e método para aquecer um volume de tecido sob a superfície da pele de um indivíduo
WO2007019539A3 (en) Methods and devices for delivering agents across biological barriers
WO2008036658A3 (en) Method and system for controlled infusion of therapeutic substances
ATE485072T1 (de) Katheter mit distaler wirkstofffreisetzungseinheit
WO2009120484A3 (en) Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
WO2011064780A3 (en) Analyte monitoring and fluid dispensing system
ZA201201176B (en) Catheter comprising a protection system for aspirating,fragmenting and extracting removable material from hollow bodies and/or vessels,in particular of the human or animal body
EP2348982A4 (en) SYSTEM AND METHOD FOR DETERMINING THE POSITION OF THE TIP OF A MEDICAL CATHETER IN THE BODY OF A PATIENT
WO2008043065A3 (en) System and method for percutaneous delivery of electrical stimulation to a target body tissue
WO2007067920A3 (en) Imaging method, device and system
IL180261A0 (en) Device, system and method for in-vivo sensing of a body lumen
EP1988928A4 (en) MAGNETIC NANOCOMPOSITE FOR CONTRAST, INTELLIGENT CONTRAST, DRUG DELIVERY FOR SIMULTANEOUS DIAGNOSIS AND TREATMENT AND DISPOSAL FOR TARGET SUBSTANCE
WO2006069677A3 (en) Combination comprising an agent providing a signal, an implant material and a drug
WO2007082189A3 (en) A medical delivery system of a medically useful payload
AR063136A1 (es) Micro- bomba peristaltica con cabezal de bomba intercambiable
WO2009147641A3 (en) A device and a system for delivery of biological material
WO2007120557A3 (en) Method and apparatus of low strengh electric field network-mediated delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792051

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009526431

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12671856

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08792051

Country of ref document: EP

Kind code of ref document: A1